Real world evidence studies of vedolizumab vs. ustekinumab in Crohn's disease and ulcerative colitis
Dr Marek Tyl
Institution or company
Takeda UK Ltd.
The project is to perform a feasibility study to assess whether (based on data contained in the IBD BioResource database) it is possible to undertake studies which:-
(a) Assess persistence on treatment for vedolizumab vs ustekinumab in the second line biologic setting in Crohn's disease.
(b) Assess persistence on therapy in ulcerative colitis, comparing patients treated with vedolizumab (first line treatment) followed by an anti-TNF (second line treatment) versus those treated with anti-TNF (first line treatment) followed by vedolizumab (second line treatment) versus those treated with one anti-TNF agent (first line treatment) followed by another anti-TNF agent (second line treatment).
We hope the results will help inform treating physicians on:-
1) Making the decision as to which of the two commonly used therapies (vedolizumab / ustekinumab) to prescribe following failure of first line biologic therapy (usually with an anti-TNF) for patients with Crohn's disease.
2) To help inform clinicians making the decision as to which of the two commonly used therapies (vedolizumab / anti-TNF) to initiate as first biologic therapy for patients with ulcerative colitis.